皮下C.E.R.A.用于慢性肾脏病贫血患儿维持治疗:2期开放标签单臂多中心研究
本研究为2期开放标签单臂多中心研究,纳入40例0.4-17.7岁接受促红细胞生成素刺激剂维持治疗的慢性肾脏病贫血患儿,每4周皮下注射C.E.R.A.,起始剂量基于既定转换因子。主要终点达标:血红蛋白平均升高0.48g/dL(95%CI 0.15-0.82),标准差±1.03,均在预设界限内。结论认为经定义转换因子确定起始剂量后,患儿可安全有效地从ESA转换为每4周皮下C.E.R.A.。
要点
- 40例慢性肾脏病贫血患儿接受每4周皮下C.E.R.A.,起始剂量基于定义转换因子。
- 血红蛋白平均升高0.48g/dL(95%CI 0.15-0.82),95%CI与标准差均在预设界限内。
- 38例中24例血红蛋白维持于10-12g/dL目标范围,19例维持于基线±1g/dL内。
核心结论
- 慢性肾脏病贫血患儿无论是否接受透析,使用定义转换因子确定起始剂量后,可安全有效地从ESA维持治疗转换为每4周皮下C.E.R.A.。
研究设计与样本
- 2期、开放标签、单臂、多中心研究。
- 纳入40例0.4-17.7岁、接受ESA维持治疗的慢性肾脏病贫血患儿,包括透析和非透析患者。
- 干预为每4周皮下注射C.E.R.A.,起始剂量基于定义转换因子。
- 主要终点为基线与评估期之间血红蛋白浓度变化,同时评估次要疗效指标和安全性。
主要发现
- 血红蛋白浓度平均升高0.48g/dL,95%CI为0.15-0.82,标准差为±1.03,均在预设界限(分别为-1至1g/dL和<1.5g/dL)内。
- 38例中24例平均血红蛋白维持于10-12g/dL目标范围,19例维持于基线±1g/dL内。
- C.E.R.A.皮下剂量中位数随时间下降。
- 关键亚组(年龄组、透析类型、既往ESA治疗)的疗效与主要结果一致。
- 38例完成核心期,25例选择进入安全性扩展期;安全性与此前研究一致,无新信号。
临床怎么用
- 作者认为,经定义转换因子确定起始剂量后,患儿可安全有效地从ESA维持治疗转换为每4周皮下C.E.R.A.。
局限性
- 单臂、开放标签研究。
- 样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The optimum starting dose of intravenous continuous erythropoietin receptor activator (C.E.R.A.) has been previously determined; this study ascertains the optimum starting dose of subcutaneous C.E.R.A. administration in pediatric patients. STUDY DESIGN: Phase 2, open-label, single-arm, multicenter study. SETTING & PARTICIPANTS: Patients aged 3 months to 17 years with renal anemia and chronic kidney disease (CKD; including those treated with maintenance dialysis and those not treated with dialysis) who were receiving maintenance treatment with erythropoiesis-stimulating agents (ESAs). INTERVENTION: Subcutaneous C.E.R.A. administration every 4 weeks (starting dose was based on defined conversion factors). OUTCOME: The primary outcome was the change in hemoglobin concentration between the baseline and evaluation period for each patient. Secondary efficacy measures and safety were also evaluated. RESULTS: Forty patients aged 0.4-17.7 years were enrolled. The study achieved its primary outcome: the mean change in hemoglobin concentration was an increase of 0.48g/dL; the 95% confidence interval (0.15-0.82) and standard deviation (±1.03) were within the prespecified boundaries (-1 to 1g/dL and<1.5g/dL, respectively). Mean hemoglobin concentrations were maintained within the target 10-12g/dL range in 24 of 38 patients and within±1g/dL of the baseline in 19 of 38 patients, and the median C.E.R.A. subcutaneous dose decreased over time. Efficacy in key subgroups (age group, dialysis type, prior ESA treatment) was consistent with the primary outcome. Thirty-eight patients completed the core period; 25 chose to enter the safety extension period. Safety was consistent with prior studies, with no new signals. LIMITATIONS: Single-arm and open-label study; small sample size. CONCLUSIONS: Pediatric patients with anemia secondary to CKD who were on, or not on, dialysis could be safely and effectively switched from maintenance ESAs to subcutaneous C.E.R.A. administered every 4 weeks, using defined dose-conversion factors to determine the optimum starting dose. FUNDING: F. Hoffmann-La Roche Ltd. TRIAL REGISTRATION: The SKIPPER trial registered at ClinicalTrials.gov with study number NCT03552393. PLAIN-LANGUAGE SUMMARY: Anemia, a complication of chronic kidney disease, is associated with poor quality of life and an increased risk of hospitalization and mortality. The current treatments for anemia include iron therapy and erythropoiesis-stimulating agents (ESAs); however, the relatively short half-lives of the ESAs epoetin alfa/beta or darbepoetin alfa may require more frequent dosing and hospital visits compared with the ESA known as continuous erythropoietin receptor activator (C.E.R.A.). A previous study demonstrated that children aged 5 years or more with anemia associated with chronic kidney disease who were on hemodialysis could be switched to intravenous C.E.R.A. from their existing epoetin alfa/beta or darbepoetin alfa treatment. This study provides evidence that subcutaneous C.E.R.A. can safely and effectively treat anemia in children, including those aged<5 years and regardless of whether they were on dialysis or the type of dialysis they received (peritoneal dialysis or hemodialysis).
引用
- Warady BA, Meyer Reigner S, Tirodkar C, et al. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study. Am J Kidney Dis. 2022. PMID: 36587890. doi:10.1053/j.ajkd.2022.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。